A Randomized Comparison of the Healing Response Between the Firehawk Stent and the Xience Stent in Patients With ST-Segment Elevation Myocardial Infarction at 6 Months of Follow-Up (TARGET STEMI OCT China Trial): An Optical Coherence Tomography Study

Abstract

BackgroundThe healing response of the Firehawk stent in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear.AimWe compared the vascular healing of a biodegradable polymer sirolimus-eluting stent (Firehawk) vs. a durable polymer everolimus-eluting stent (Xience) at 6 months after percutaneous coronary intervention (PCI) in patients with STEMI.MethodsIn this prospective, multicenter, randomized, non-inferiority study, patients within 12 h of STEMI onset were randomized in a ratio of 1:1 to receive Firehawk or Xience stents. Optical coherence tomography (OCT) follow-up was performed 6 months after the index procedure and assessed frame by frame. The primary endpoint was the neointimal thickness (NIT) at 6 months evaluated by OCT. The safety endpoint was target lesion failure (TLF) at 12 months.ResultsThe Firehawk stent was non-inferior to the Xience stent in terms of the neointimal thickness (73.03 ± 33.30 μm vs. 78.96 ± 33.29 μm; absolute difference: −5.94 [one-sided 95% lower confidence bound: −23.09]; Pnon−inferiority < 0.001). No significant difference was observed between the Firehawk and Xience groups regarding the percentage of uncovered struts (0.55 [0.08, 1.32]% vs. 0.40 [0.21, 1.19]%, P = 0.804), the percentage of malapposed struts (0.17 [0.00, 1.52]% vs. 0.17 [0.00, 0.69]%, P = 0.662), and the healing score (1.56 [0.23, 5.74] vs. 2.12 [0.91, 3.81], P = 0.647). At 12 months, one patient in the Firehawk group experienced a clinically indicated target lesion revascularization. No other TLF events occurred in both groups. Independent risk factors of the NIT included body mass index, hyperlipidemia, B2/C lesions, thrombus G3–G5, thrombus aspiration, and postdilation pressure.ConclusionIn patients with STEMI, Firehawk was non-inferior to Xience in vascular healing at 6 months. Both stents exhibited nearly complete strut coverage, moderate neointimal formation, and minimal strut malapposition.Clinical Trial NumberNCT04150016.

Epidemiology and current management of cardiovascular disease in China

“…In a multi-center randomized controlled trial in China, 212 patients with small-vessel native coronary disease (reference vessel diameter: 2.0-2.75 mm, lesion length ≤ 25 mm) were randomized to receive a domestic biolimus-coated balloon (BCB) or an uncoated balloon. [44] In the per-protocol population, angiographic late lumen loss at 9 months was 0.16 ± 0.29 mm in the BCB group versus 0.30 ± 0.35 mm in the plain balloon group (P = 0.001). Late luminal enlargement (positive remodeling) occurred in 29.7% of patients in the BCB group versus 9.8% of patients in the plain balloon group.…”

Primary drug-coated balloon angioplasty with provisional stenting versus primary stenting for the treatment of de novo coronary artery lesions: REC-CAGEFREE I trial rationale and design

“…The off-line quantitative coronary angiography (QCA) [40] and quantitative ow ratio (QFR) [41] assessment by an independent Corelab will be performed at baseline (pre-and post-PCI). Routine followup angiography in the absence of symptoms was not recommended.…”

Drug-coated balloon angioplasty with provisional stenting versus primary stenting for the treatment of de novo coronary artery lesions: REC-CAGEFREE I trial rationale and design

“…The off-line quantitative coronary angiography (QCA) [38] and quantitative flow ratio (QFR) [39] assessment by an independent Corelab will be performed at baseline (pre-and post-PCI). Routine follow-up angiography in the absence of symptoms was not recommended.…”